Plain-English translation of NCT06710756 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which uses a radioactive form of lead to deliver powerful radiation directly to cancer cells. The medication works by targeting a protein called FAP that appears on cancer cells and the tissues surrounding them. Researchers hope this approach will be more effective and safer than current treatments.
Many advanced cancers do not respond well to standard treatments, and doctors need new options. This medication represents a new class of targeted therapies designed to deliver radiation more precisely to tumors while sparing healthy tissue.
You likely qualify if…
You likely don't qualify if…
First, you will receive an imaging scan using a tracer version of the medication to confirm your cancer has the target protein. If eligible, you will then receive the therapeutic medication as an infusion. The trial has two parts: the first part tests different doses to find the safest and most effective level, and the second part treats more patients at that optimal dose. You will have regular follow-up visits and imaging scans to monitor how well the treatment works and check for side effects.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States